XH-30002

N/A

Report date: 2025/08/27 14:48:28
NME

Base Information

Drug NameXH-30002
Drug Alias NameXH-30002JRF104JRF-104
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 4 inhibitorsCyclin-dependent kinase 6 inhibitors
TargetsCyclin-dependent kinase 4Cyclin-dependent kinase 6
Therapy Area/IndicationsSolid tumoursEsophageal Squamous Cell Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Xunhe Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFujian Cancer HospitalShanghai Xunhe Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursEsophageal Squamous Cell Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A